Abstract: The present invention provides novel stem cells, nucleotide sequences and proteins therefrom. More specifically, the present invention provides Pax7+/Myf5? stem cells and methods for identifying and isolating them. Also provided is a MEGF10 nucleotide sequence and protein.

Abstract: The present invention provides novel stem cells, nucleotide sequences and proteins therefrom. More specifically, the present invention provides Pax7+/Myf5? stem cells and methods for identifying and isolating them. Also provided is a MEGF10 nucleotide sequence and protein.

Abstract: The present invention provides novel stem cells, nucleotide sequences and proteins therefrom. More specifically, the present invention provides Pax7+/Myf5? stem cells and methods for identifying and isolating them. Also provided is a MEGF10 nucleotide sequence and protein.

Abstract: The present invention relates generally to adjuvants, and in particular to methods and products utilizing a synergistic combination of immunostimulatory oligonucleotides having at least one unmethylated CpG dinucleotide (CpG ODN) and a non-nucleic acid adjuvant. Such combinations of adjuvants may be used with an antigen or alone. The present invention also relates to methods and products utilizing immunostimulatory oligonucleotides having at least one unmethylated CpG dinucleotide (CpG ODN) for induction of cellular immunity in infants.

Abstract: The present invention provides the use of nucleic acid sequences and/or amino acid sequences in the preparation of a vaccine for the protection of fish against infectious salmon anaemia virus. Specifically, such vaccines contain at least one nucleic acid sequence which is derived from ISAV or synthetically prepared analogues thereof, or substantially homologous sequences. These nucleic acid sequences are transcripted and translated into peptide sequences which are incorporated into a vaccination strategy to induce and immune response to the surface antigens of ISAV and therefore ISAV itself. Therefore both the use of a vaccine against ISAV, and the incorporation of peptide sequences is herein described.

Abstract: The present invention provides novel stem cells, nucleotide sequences and proteins therefrom. More specifically, the present invention provides Pax7+/Myf5? stem cells and methods for identifying and isolating them. Also provided is a MEGF10 nucleotide sequence and protein.

Abstract: The present invention provides the use of nucleic acid sequences and/or amino acid sequences in the preparation of a vaccine for the protection of fish against infectious salmon anemia virus. Specifically, such vaccines contain at least one nucleic acid sequence which is derived from ISAV or synthetically prepared analogues thereof, or substantially homologous sequences. These nucleic acid sequences are transcripted and translated into peptide sequences which are incorporated into a vaccination strategy to induce and immune response to the surface antigens of ISAV and therefore ISAV itself. Therefore both the use of a vaccine against ISAV, and the incorporation of peptide sequences is herein described.

Abstract: The present invention provide PCSK9 polypeptides, fragments thereof and methods of modulating PCSK9 phosphorylation and low density lipoprotein degradation.

Abstract: The invention provides methods for treating cancer cells in a host by infecting the cancer cells with one or more strains of oncolytic virus, in conjunction with treating the host with an amount of an HDI that is effective to augment the cancer-cell-specific oncolytic infection.

Abstract: The invention provides methods for treating tumours, such as solid tumours, in a host. The methods may involve infecting the tumour with an amount of one or more strains of oncolytic virus. The virus will generally be selected to be effective to cause a lytic infection of tumour cells within the tumour. In various embodiments, the host neutrophil response to the lytic infection may be modulated, so that during the course of the lytic infection, the host has an initial neutrophil response and a secondary neutrophil response, these two responses being different in some material respect. For example, the secondary neutrophil response may mediate a greater degree of apoptotic killing of tumour cells than does the initial neutrophil response.

Abstract: The invention provides compositions and methods for treating neoplastic disease, such as cancer, with an oncolytic virus, such as VSV. A carrier cell is used to target a diseased tissue, and to cloak the oncolytic virus from surveillance by the subject's immune system during a targeting interval. Following delivery of the virus to the target tissue, the lysis of the carrier cell, and of the target cell, by the oncolytic virus, promotes an adaptive tumouricidal immune response. A wide variety of disparate carrier cells may be used, in conjunction with a promiscuous oncolytic virus having broad tropism, in an approach which facilitates successive treatments in which a new carrier will not be susceptible to an adaptive immune response mounted against previously used carriers. The promiscuity of the virus also facilitates lysis of carrier cells and target cells that are allogenic or xenogenic.

Abstract: Compositions and methods for modulating proliferation and/or lineage commitment of stem cells by modulating the Wnt signalling pathways. Modulators of the Wnt signalling pathways and screening methods to identify modulators are also provided. The methods of the invention may be conducted in vitro or in vivo to induce or inhibit stem cell proliferation and/or lineage commitment, and are particularly useful for in vivo stimulation of proliferation and/or lineage commitment of resident stem cells in a tissue.

Abstract: The invention provides inhibitors of Ste20-like kinase (SLK inhibitors). The inhibitors may be employed to modulate proliferation of cells, including tumor and cancer cells. The inhibitors also may be employed to inhibit motility or migration of cells, including cancer and tumor cells.

Abstract: The present invention provides novel stem cells, nucleotide sequences and proteins therefrom. More specifically, the present invention provides Pax7+/Myf5? stem cells and methods for identifying and isolating them. Also provided is a MEGF10 nucleotide sequence and protein.

Abstract: The present invention pertains to an articulating joint that is disengageable between two modes of operation: unidirectional movement of the joint or bi-directional movement of the joint, with features that allow the mode to be automatically switched as required. When fully locked, the joint inhibits joint flexion while allowing joint extension. When actuated, a locking mechanism is disengaged to allow both uninhibited flexion and extension of the joint.

Abstract: The present invention provides cells transformed with a nucleotide sequence encoding Pax7, Pax3 or both. The present invention also pertains to Pax-encoding vector that comprises a sequence encoding Pax7, Pax3 or an active variant or fragment thereof, which can be used to induce myogenic differentiation of stem cells. The present invention further pertains to methods of preparing the Pax-encoding vector. Also provided is a method of inducing myogenic differentiation in stem cells and treating a subject with the cells.

Abstract: The present invention provides the use of nucleic acid sequences and/or amino acid sequences in the preparation of a vaccine for the protection of fish against infectious salmon anaemia virus. Specifically, such vaccines contain at least one nucleic acid sequence which is derived from ISAV or synthetically prepared analogues thereof, or substantially homologous sequences. These nucleic acid sequences are transcripted and translated into peptide sequences which are incorporated into a vaccination strategy to induce and immune response to the surface antigens of ISAV and therefore ISAV itself. Therefore both the use of a vaccine against ISAV, and the incorporation of peptide sequences is herein described.

Abstract: The present invention provides the use of nucleic acid sequences and/or amino acid sequences in the preparation of a vaccine for the protection of fish against infectious salmon anaemia virus. Specifically, such vaccines contain at least one nucleic acid sequence which is derived from ISAV or synthetically prepared analogues thereof, or substantially homologous sequences. These nucleic acid sequences are transcripted and translated into peptide sequences which are incorporated into a vaccination strategy to induce and immune response to the surface antigens of ISAV and therefore ISAV itself. Therefore both the use of a vaccine against ISAV, and the incorporation of peptide sequences is herein described.

Abstract: A bio-synthetic matrix comprising a hydrogel which is formed by cross-linking a synthetic polymer and a bio-polymer is provided. The matrix is robust, biocompatible and non-cytotoxic and is capable of supporting cell in-growth in vivo. The matrix can be tailored to further comprise one or more bioactive agents. The matrix may also comprise cells encapsulated and dispersed therein, which are capable of proliferating upon deposition of the matrix in vivo. Methods of preparing the bio-synthetic matrix and the use of the matrix in vivo for tissue engineering or drug delivery applications are also provided.

Abstract: The present invention provides the use of nucleic acid sequences and/or amino acid sequences in the preparation of a vaccine for the protection of fish against infectious salmon anaemia virus. Specifically, such vaccines contain at least one nucleic acid sequence which is derived from ISAV or synthetically prepared analogues thereof, or substantially homologous sequences. These nucleic acid sequences are transcripted and translated into peptide sequences which are incorporated into a vaccination strategy to induce and immune response to the surface antigens of ISAV and therefore ISAV itself. Therefore both the use of a vaccine against ISAV, and the incorporation of peptide sequences is herein described.